TICKERNERD
Menu
PLRXPLRXHealthcare · Biotechnology

PLRX Stock Forecast: Pliant Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.16
+3.13% on the day

The 5 Wall Street analysts covering Pliant Therapeutics, Inc. hold a median 12-month price target of $2.5 — +116.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$71.5M
Ticker Nerd rank
66 / 100
Median analyst target
$2.50
Analysts covering
5
Total return, dividends reinvested
1W
+7.9%
1M
+6.0%
YTD
−5.3%
1Y
−20.3%
From 52W high
−38.2%
From 52W low
+12.1%
$1.03
$1.87
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PLRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pliant Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
66 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
88
Growth
86
Volatility
80
Accruals
79
Size
79
Quality
59
Momentum
29
Revisions
28
Value
17

Issuance (88): The share count has been shrinking and the company is not leaning on new borrowing.

Value (17): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PLRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PLRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$1.50$2.00$2.50$3.00Oct 25Jan 26Apr 26Jul 26PLRXHigh $3.00Median $2.50Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
0 Buy4 Hold1 Sell
Low $2.00Median $2.50High $3.00

The green dot is the last close — the median target sits +116.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Mar 2026Canaccord GenuityMaintainsHold$4.00 → $3.00
12 Mar 2026Piper SandlerMaintainsOverweight$4.00 → $3.00
7 Nov 2025RBC CapitalMaintainsSector Perform—
10 Oct 2025JP MorganDowngradeUnderweight—
8 Aug 2025Piper SandlerMaintainsOverweight—
18 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
4 Mar 2025Cantor FitzgeraldReinstatesNeutral—
4 Mar 2025CitigroupMaintainsNeutral—
4 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
4 Mar 2025NeedhamDowngradeHold—
4 Mar 2025RBC CapitalMaintainsSector Perform—
4 Mar 2025Wells FargoMaintainsEqual-Weight—
3 Mar 2025Leerink PartnersDowngradeMarket Perform—
14 Feb 2025HC Wainwright & Co.ReiteratesNeutral—
14 Feb 2025NeedhamReiteratesBuy—
10 Feb 2025Canaccord GenuityDowngradeHold—
10 Feb 2025CitigroupDowngradeNeutral—
10 Feb 2025HC Wainwright & Co.DowngradeNeutral—
10 Feb 2025JP MorganDowngradeNeutral—
10 Feb 2025NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PLRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PLRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Pliant Therapeutics, Inc. (PLRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.5×

Cheaper than 80% of US stocks

Price / sales
—
Price / book
0.5×

Cheaper than 85% of US stocks

EV / EBITDA
0.6×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−50.3%

Higher than 21% of US stocks

Return on assets
−23.3%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PLRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PLRXPliant Therapeutics, Inc.$71.5M
66
LONALeonaBio, Inc.$71.5M
44
IBIOiBio, Inc.$71.0M
26
OSTXOS Therapies, Inc.$70.8M
29
PMVPPMV Pharmaceuticals, Inc.$70.5M
68
SERSerina Therapeutics, Inc.$72.9M
18
RNTXRein Therapeutics, Inc.$70.0M
37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pliant Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PLRX news & analysis

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

GlobeNewsWire · 18 Aug 2026positive

Pliant Therapeutics announced that the FDA granted Fast Track designation to PLN-101095, an oral dual inhibitor of αvβ8 and αvβ1 integrins, when used in combination with pembrolizumab for the potential treatment of solid tumors resistant to immune checkpoint inhibitors.

Why it matters — The Fast Track designation may expedite development and review of PLN-101095 in combination with pembrolizumab, a key pipeline candidate for Pliant Therapeutics.

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 11 Aug 2026positive

Pliant Therapeutics issued a corporate update and reported its second quarter 2026 financial results. The company noted strong enrollment in FORTIFY, a Phase 1b indication expansion trial of PLN-101095, and announced the appointment of oncology drug development leaders Flavia Borellini, Ph.D. and Robert Iannone, M.D.

Why it matters — A PLRX watcher would care because strong enrollment in the FORTIFY trial and the addition of experienced oncology leaders signal continued progress on PLN-101095 and the company's broader pipeline.

FAQ

Frequently asked questions about PLRX stock

What is the PLRX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Pliant Therapeutics, Inc. have a median 12-month price target of $2.5, with estimates ranging from $2 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PLRX stock a buy right now?

Of the 5 analysts covering Pliant Therapeutics, Inc., 0 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Pliant Therapeutics, Inc. 66 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PLRX?

As at 22 Aug 2026, Pliant Therapeutics, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (88 of 100).

Will PLRX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +116.5% from the last close, and Ticker Nerd's factor model ranks Pliant Therapeutics, Inc. 66 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PLRX stock forecast for 2030?

No analyst covering Pliant Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $3 over the next 12 months.

How has PLRX stock performed over the past year?

Pliant Therapeutics, Inc. returned -20.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pliant Therapeutics, Inc. do?

Pliant Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics for fibrotic diseases, solid tumors, and muscular dystrophies.

What is the latest news on PLRX?

The most recent item we track (GlobeNewsWire, 18 Aug 2026): "Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors". Pliant Therapeutics announced that the FDA granted Fast Track designation to PLN-101095, an oral dual inhibitor of αvβ8 and αvβ1 integrins, when used in combination with pembrolizumab for the potential treatment of solid tumors resistant to immune checkpoint inhibitors.

Company

About Pliant Therapeutics, Inc.

Pliant Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics for fibrotic diseases, solid tumors, and muscular dystrophies. The company leverages integrin receptor biology to create novel small-molecule inhibitors and monoclonal antibodies that modulate key pathways like TGF-β signaling, aiming for tissue-specific targeting to address unmet needs in these areas. Its pipeline features bexotegrast, an oral dual selective inhibitor of αvβ6 and αvβ1 integrins, previously advanced for idiopathic pulmonary fibrosis and primary sclerosing cholangitis; PLN-101095, an oral dual inhibitor of αvβ8 and αvβ1 integrins under evaluation in Phase 1 trials for advanced solid tumors resistant to immune checkpoint inhibitors, both as monotherapy and with pembrolizumab; and PLN-101325, a monoclonal antibody agonist of α7β1 integrin with regulatory clearance for Phase 1 studies in muscular dystrophies. Pliant Therapeutics Inc. maintains a proprietary discovery platform with integrin-binding molecules and screening assays to support tissue-specific drug delivery across multiple indications. Incorporated in 2015 and headquartered in South San Francisco, California, the company plays a significant role in advancing precision therapies within the biotechnology sector.

CEO Dr. Bernard Coulie M.B.A., M.D., Ph.D. · 49 employees · United States · https://pliantrx.com